EKF Diagnostics Holdings PLC Posting of Annual Report &Accounts & Notice of AGM (3690W)
23 Abril 2021 - 01:00AM
UK Regulatory
TIDMEKF
RNS Number : 3690W
EKF Diagnostics Holdings PLC
23 April 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Posting of Annual Report & Accounts
And Notice of Annal General Meeting
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business, c onfirms that the Annual Report and
Accounts for the year ended 31 December 2020 ("2020 Annual Report")
and the Notice of the 2021 Annual General Meeting ("AGM") have now
been published on the Company's website at:
https://www.ekfdiagnostics.com/documents-reports.html
The 2020 Annual Report, the Notice of AGM and details voting by
proxy will be posted to shareholders who have not consented to
receive electronic communications today, 23 April 2021.
The AGM is to be held on 19 May 2021 at 10.30am at the Company's
offices at Avon House, 19 Stanwell Road, Penarth, Cardiff CF64 2EZ
and will consider the Resolutions set out in the Notice of AGM.
Due to the UK Government restrictions on public gatherings as a
consequence of the COVID-19 pandemic, it will not be possible for
shareholders to attend the AGM in person. The Board, with this in
mind and in accordance with the Corporate Insolvency and Governance
Act 2020, has therefore decided that the AGM will be held as a
'closed' meeting with the minimum number of Directors and officers
who hold shares, present, to form the necessary quorum.
Regrettably, other shareholders will not be permitted to attend the
meeting in person.
The Company will provide a facility for shareholders to join the
AGM either online or telephonically and there will be an
opportunity for shareholders to ask questions. In order to
facilitate the process, the Directors would request that
Shareholders register for the meeting and submit questions in
advance, before 10.30 a.m. 17 May 2021.
To register for dial-in details and to submit any questions
please contact Walbrook PR via email at ekf@walbrookpr.com or call
+44 (0)20 7933 8787.
Proxy voting
Shareholders will not receive a hard copy form of proxy for the
2021 AGM in the post. Instead, Shareholders will be able to vote
electronically using the link www.signalshares.com. Proxy votes
must be received no later than 10.30a.m. on 17 May 2021.
Shareholders may request a hard copy form of proxy directly from
the Registrars, Link Group, on Tel: 0371 664 0300. Calls are
charged at the standard geographic rate and will vary by provider.
Calls outside the United Kingdom will be charged at the applicable
international rate. Lines are open between 09:00 - 17:30, Monday to
Friday excluding public holidays in England and Wales.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas / Tom
Salvesen
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities in the USA for a variety of life science
products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAITMFTMTJTBRB
(END) Dow Jones Newswires
April 23, 2021 02:00 ET (06:00 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024